Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 24, 2025
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that …
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com
GlobeNewswire
·
April 24, 2025
ROSEVILLE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Via IBN -- InnerScope Hearing Technologies (OTC: INND) is proud to announce the official grand opening of OTCHealthMart.com, a cutting-edge online platform designed to make healthcare products …
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET
GlobeNewswire
·
April 24, 2025
SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …
ICU Medical Announces Time of First Quarter 2025 Earnings Conference Call
GlobeNewswire
·
April 24, 2025
SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2025 earnings release and conference …
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial …
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR
GlobeNewswire
·
April 24, 2025
THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof- …
SS Innovations to Uplist to Nasdaq
GlobeNewswire
·
April 24, 2025
FORT LAUDERDALE, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
Sofwave’s liftHD Body Contouring Applicator to Debut at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025
GlobeNewswire
·
April 24, 2025
Launch of the liftHD body applicator provides opportunity for next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance in order to achieve SUPERB results beyond the face Four abstract poster presentations …
Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton
GlobeNewswire
·
April 24, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
GlobeNewswire
·
April 24, 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology …
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
GlobeNewswire
·
April 24, 2025
ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter …
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
GlobeNewswire
·
April 24, 2025
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March …
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
GlobeNewswire
·
April 24, 2025
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment
GlobeNewswire
·
April 24, 2025
Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists. Northstrive believes the FDA …
SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform
GlobeNewswire
·
April 24, 2025
All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA) Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering medication ALISO VIEJO, Calif., April 24, 2025 (GLOBE …
NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the 2025 Robert W. Berliner Award for Excellence in Renal Physiology
GlobeNewswire
·
April 24, 2025
April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder and CMO, Jeff M. Sands, M.D., is the recipient of the 2025 Robert W. Berliner Award for Excellence in Renal …
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
GlobeNewswire
·
April 24, 2025
– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – …
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 24, 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today …
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
GlobeNewswire
·
April 24, 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first …
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
GlobeNewswire
·
April 24, 2025
Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad- …